AMicale des COXiens

Forum des actionnaires particuliers de NicOx
 
AccueilAccueil  GalerieGalerie  S'enregistrerS'enregistrer  ConnexionConnexion  

Partagez | 
 

 B&L achète ISTA !!!

Voir le sujet précédent Voir le sujet suivant Aller en bas 
AuteurMessage
p.sivida



Nombre de messages : 113
Date d'inscription : 14/11/2010

MessageSujet: B&L achète ISTA !!!   Mar 27 Mar - 9:55



RSS Content
Bausch + Lomb to Acquire ISTA Pharmaceuticals
Combination Enhances Bausch + Lomb's Growing Pharmaceutical Business; Creates Comprehensive Portfolio of Medicines; and Dramatically Expands D&R Pipeline
MADISON, NJ and IRVINE, CA, Mar 26, 2012 (MARKETWIRE via COMTEX) --Bausch + Lomb, the global eye health company, and ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced that they have signed a definitive agreement under which Bausch + Lomb ("the Company") will acquire ISTA for $9.10 per share in cash, or a total of approximately $500 million. The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the second quarter of 2012.

Bausch + Lomb's acquisition of ISTA accelerates the company's strategy to strengthen its pipeline and marketed products and capabilities. The transaction is expected to drive growth and high performance for the long term.

The combination adds ISTA's portfolio of industry-proven non-steroidal, anti-inflammatory, allergy, glaucoma and spreading agents to Bausch + Lomb's robust, complementary portfolio of existing Rx ophthalmology and OTC eye health products. The companies also have complementary development pipelines. ISTA's pipeline includes candidates in various stages of development to treat various ocular conditions including inflammation and pain, while Bausch + Lomb's pipeline of pharmaceutical innovations include the first of a new class of ocular anti-inflammatory agents to come along in decades, and a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

"ISTA is an excellent strategic fit with Bausch + Lomb's rapidly growing pharmaceutical business, and this combination represents an important step in Bausch + Lomb's commitment to becoming the best global eye health company," said Brent Saunders, president and chief executive officer, Bausch + Lomb. "Because Bausch + Lomb already manufactures nearly all of ISTA's current U.S. products, our companies have known each other well for many years. We share a strong overlapping customer base in the U.S., a commitment to serving our physicians and patients and a track record of developing meaningful medical advances in eye health. With this combination, we will significantly enhance our pharmaceutical pipeline, nearly doubling the number of mid- to late-stage innovations. We look forward to delivering the benefits of this combination to customers, patients, employees and partners of both companies."

"Along with the rest of our Board of Directors, I am pleased that the tremendous assets ISTA's people have created with our products and pipeline have been recognized by Bausch + Lomb, a global leader in eye health, and that we were able to finalize a transaction after a thorough process that delivers shareholders an important return on their investment in ISTA," said Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "Both companies have a significant commitment to serving the needs of the healthcare industry, eye care professionals and patients alike. ISTA's portfolio of prescription eye and allergy products is a natural extension of Bausch + Lomb's pharmaceutical business focus. Together, we create an impressive platform to commercialize new eye care and allergy products already under development."

The transaction, which is expected to be accretive to Bausch + Lomb's EBITDA in the first year after close, is subject to regulatory approval and other customary closing conditions, including the approval of ISTA's shareholders. The companies will continue to operate independently until completion of the transaction.

Bausch + Lomb currently intends to finance the acquisition with a combination of cash on hand and the proceeds of a $350 million incremental term loan facility to be provided under its existing credit facility and available borrowings under its existing revolving credit facilities or, alternatively, to obtain other financing in lieu of the foregoing (provided that Bausch + Lomb intends in all cases to have a combination of cash on hand and committed financing sufficient to finance the acquisition). Bausch + Lomb has obtained commitments for the full amount of the incremental facility from Citigroup Global Markets Inc., JPMorgan Chase Bank, N.A., Credit Suisse AG, Goldman Sachs Bank USA, and Bank of America Merrill Lynch.

This purchase price reflects a 10% premium to the share price as of the market close on March 23, 2012, a 40% premium to the proposal letter ISTA publicly confirmed it received from Valeant Pharmaceuticals and a 134% premium to the share price on December 15, 2011, the trading day prior to ISTA's announcement of the proposal letter it received from Valeant Pharmaceuticals and the ISTA board's announcement of its intention to review strategic options.

Goldman, Sachs & Co. served as financial advisor to Bausch + Lomb in this transaction and Cleary Gottlieb Steen & Hamilton LLP served as legal counsel. Greenhill & Co. served as financial advisor to ISTA and Stradling Yocca Carlson & Rauth and WilmerHale LLP served as legal advisors.

About ISTA Pharmaceuticals ISTA Pharmaceuticals, Inc. is a fast growing and the third largest branded prescription eye care business in the United States with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. Headquartered in Irvine, California, ISTA generated revenues of $160 million in 2011. For additional information about ISTA, please visit the corporate website at www.istavision.com.

About Bausch + Lomb Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs roughly 11,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC ISTA plans to file with the SEC and mail to its stockholders a Proxy Statement in connection with the transaction. The Proxy Statement will contain important information about ISTA, Bausch + Lomb, the transaction and related matters. Investors and security holders are urged to read the Proxy Statement carefully when it is available.

Investors and security holders will be able to obtain free copies of the Proxy Statement and other documents filed with the SEC by ISTA through the web site maintained by the SEC at www.sec.gov.

In addition, investors and security holders will be able to obtain free copies of the Proxy Statement from ISTA by contacting Investor Relations at 949-789-3159 or jherbert@istavision.com.

ISTA and Bausch + Lomb and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ISTA's stockholders with respect to the transactions contemplated by the merger agreement. Information regarding ISTA's directors and executive officers is contained in ISTA's Annual Report on Form 10-K for the year ended December 31, 2011, its proxy statement dated November 1, 2011, and its Current Report on Form 8-K filed December 6, 2011, which are filed with the SEC. As of February 24, 2012, ISTA's directors and officers beneficially owned approximately 5,481,128 shares, or 13.10%, of ISTA's common stock. Additional information regarding the interests of the participants in the solicitation of proxies in connection with the transaction will be included in the Proxy Statement.

SAFE HARBOR FOR FORWARD LOOKING STATEMENTS Statements in this document regarding the proposed transaction between Bausch + Lomb and ISTA, the expected timetable for completing the transaction, benefits and synergies of the transaction, and any other statements about Bausch + Lomb or ISTA managements' future expectations, beliefs, goals, plans or prospects constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," estimates and similar expressions) should also be considered to be forward looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward looking statements, including the ability to consummate the transaction, and the other factors described in ISTA's Annual Report on Form 10-K for the year ended December 31, 2011. Bausch + Lomb and ISTA disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this document.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
adarme



Nombre de messages : 447
Age : 47
Localisation : lot et garonne
Date d'inscription : 13/10/2008

MessageSujet: Re: B&L achète ISTA !!!   Mar 27 Mar - 11:35

fatch! j'ai eu peur...
j ai cru que nicox achetait B&L... :-D

merci pour l'info Simis!

ça bouge dans l'ophtalmo; l'un des crénaux porteurs...et en croissance... ça tombe bien nan?
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
D@n (Daniel Beldio)



Nombre de messages : 3210
Age : 65
Localisation : Pays de l'Arbre et de l'Eau
Date d'inscription : 09/02/2007

MessageSujet: Re: B&L achète ISTA !!!   Mar 27 Mar - 20:01

Bien vu Simis ! Cool

ISTA était déjà courtisée en fin d'année dernière. Mais le prétendant (Valeant) n'a pas été retenu.
Source :
http://lapresseaffaires.cyberpresse.ca/economie/sante/201112/16/01-4478542-va leant-offre-327-millions-pour-ista-pharmaceuticals.php

La pharmaceutique ontarienne Valeant Pharmaceuticals International (T.VRX) a lancé une offre d'acquisition non sollicitée de 327 millions de dollars pour la californienne ISTA Pharmaceuticals, incluant la dette de cette dernière.

Valeant indique que son offre a été rejetée par ISTA plus tôt cette semaine, après des négociations qui ont débuté en octobre.

ISTA Pharmaceuticals possède un des plus importants portefeuilles de médicaments ophtalmologiques aux États-Unis, en plus de médicaments contre les allergies.

Valeant affirme que son offre représentait une prime de 68 % par rapport au cours moyen du titre d'ISTA au cours des 60 derniers jours, en date du 15 décembre. L'offre a une valeur totale de 314 millions, plus une dette de 13 millions.

La direction de Valeant s'est dite déçue du rejet de son offre et du refus des dirigeants d'ISTA de négocier.

Valeant se spécialise dans les secteurs neurologiques et dermatologiques au Canada, aux États-Unis, au Mexique, au Brésil, en Europe centrale et de l'Est, et en Australie.


Dernière édition par D@n (Daniel Beldio) le Mar 27 Mar - 20:05, édité 1 fois
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Philippe Vaillantpvailla8



Nombre de messages : 1765
Date d'inscription : 13/03/2007

MessageSujet: Re: B&L achète ISTA !!!   Mar 27 Mar - 20:05

Bausch and Lomb va pouvoir proposer des molécules à Nicox dans un deal pour la recherche développement de NO-molécules en ophtalmologie.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Contenu sponsorisé




MessageSujet: Re: B&L achète ISTA !!!   

Revenir en haut Aller en bas
 
B&L achète ISTA !!!
Voir le sujet précédent Voir le sujet suivant Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» faux lingots d'or au tungstène
» Paribas achète le Silver à 20,58$
» Achat en UE et hors UE et TVA
» Achète sections de CC8800
» #SpiceJet achète 205 #Boeing pour 20,6 milliards d'euros

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: